Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [226]

Denikitug shows immune activation and early anti-tumour activity in advanced...

Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA

Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour ( Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA )

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1...

Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers ( Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA )

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI...

Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI-resistant solid tumours ( Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA )

Oral molecular glue degrader with or without spartalizumab shows immune...

Dr Elena Garralda - Vall d’Hebron University Hospital, Barcelona, Spain

Oral molecular glue degrader with or without spartalizumab shows immune activation and tumour control in solid tumours ( Dr Elena Garralda - Vall d’Hebron University Hospital, Barcelona, Spain )

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas

Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas ( Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA )

Customised colorectal cancer early diagnosis programme can identify advanced...

Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria

Customised colorectal cancer early diagnosis programme can identify advanced adenomas and early-stage cancer ( Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF...

Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours ( Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

ASCO 2025: Developments in the treatment of soft tissue sarcoma

Dr Atif Hussein - Memorial Cancer Institute, Miami, USA

ASCO 2025: Developments in the treatment of soft tissue sarcoma ( Dr Atif Hussein - Memorial Cancer Institute, Miami, USA )

Florida Atlantic University and Memorial Cancer Institute collaboration

Dr Gregg B. Fields - Florida Atlantic University, Florida, USA

Florida Atlantic University and Memorial Cancer Institute collaboration ( Dr Gregg B. Fields - Florida Atlantic University, Florida, USA )

Future of chemotherapy and targeted therapies

Dr Natasha Rueth - Memorial Cancer Institute, Miami, USA

Future of chemotherapy and targeted therapies ( Dr Natasha Rueth - Memorial Cancer Institute, Miami, USA )

The hidden biology of addiction and cancer

Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA

The hidden biology of addiction and cancer ( Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA )

More from ecancer